Ligand Pharmaceuticals (LGND) Expected to Announce Quarterly Earnings on Thursday

by · The Markets Daily

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) is anticipated to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $1.96 per share and revenue of $58.7070 million for the quarter. Ligand Pharmaceuticals has set its FY 2025 guidance at 6.700-7.000 EPS.Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $47.63 million during the quarter, compared to the consensus estimate of $43.87 million. Ligand Pharmaceuticals had a negative net margin of 40.44% and a negative return on equity of 9.21%. The firm’s revenue was up 14.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.40 earnings per share. On average, analysts expect Ligand Pharmaceuticals to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Ligand Pharmaceuticals Stock Down 2.3%

Shares of NASDAQ:LGND opened at $184.52 on Thursday. The company has a market cap of $3.62 billion, a P/E ratio of -46.13 and a beta of 0.95. Ligand Pharmaceuticals has a 52 week low of $93.58 and a 52 week high of $194.44. The company has a 50-day moving average price of $173.09 and a 200 day moving average price of $137.55.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LGND shares. Benchmark raised their price objective on shares of Ligand Pharmaceuticals from $160.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Weiss Ratings reissued a “sell (d+)” rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, October 8th. Oppenheimer raised their price objective on shares of Ligand Pharmaceuticals from $167.00 to $190.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 3rd. Royal Bank Of Canada raised their price objective on shares of Ligand Pharmaceuticals from $155.00 to $185.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Finally, HC Wainwright raised their price objective on shares of Ligand Pharmaceuticals from $157.00 to $206.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Ligand Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $176.50.

Check Out Our Latest Stock Analysis on LGND

Insiders Place Their Bets

In other Ligand Pharmaceuticals news, Director John W. Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $179.44, for a total value of $83,798.48. Following the transaction, the director owned 45,055 shares in the company, valued at $8,084,669.20. This trade represents a 1.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jason Aryeh sold 10,000 shares of Ligand Pharmaceuticals stock in a transaction on Tuesday, September 23rd. The shares were sold at an average price of $170.81, for a total transaction of $1,708,100.00. Following the completion of the transaction, the director owned 69,289 shares in the company, valued at approximately $11,835,254.09. This trade represents a 12.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 11,401 shares of company stock worth $1,929,262. 7.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ligand Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its holdings in shares of Ligand Pharmaceuticals by 1,656.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,669 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 1,574 shares in the last quarter. Evergreen Capital Management LLC acquired a new position in shares of Ligand Pharmaceuticals during the 2nd quarter valued at $205,000. Northeast Financial Consultants Inc acquired a new position in shares of Ligand Pharmaceuticals during the 2nd quarter valued at $213,000. BNP Paribas Financial Markets lifted its holdings in shares of Ligand Pharmaceuticals by 48.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,096 shares of the biotechnology company’s stock valued at $238,000 after acquiring an additional 680 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of Ligand Pharmaceuticals during the 1st quarter valued at $344,000. Institutional investors and hedge funds own 91.28% of the company’s stock.

Ligand Pharmaceuticals Company Profile

(Get Free Report)

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.

See Also